| ◆英語タイトル：Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029
|
 | ◆商品コード：BZW23FB139
◆発行会社（リサーチ会社）：Bizwit Research & Consulting
◆発行日：2023年1月25日
◆ページ数：約200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
◆産業分野：医療
|
◆販売価格オプション
（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
Bizwit Research社によると、2021年にXXX億ドルであった世界の酵素補充療法市場規模が、2022年から2029年の間にXXX%成長すると予測されています。本調査レポートは、酵素補充療法の世界市場について調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、製品別（アガルシダーゼベータ、イミグルセラーゼ、ベラグルセラーゼアルファ、イドゥルスルファーゼ、その他）分析、疾患別（ゴーシェ病、ファブリー病、ポンペ病、ムコ多糖症、その他）分析、エンドユーザー別（病院、輸液センター＆在宅医療）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争状況、調査プロセスなどの内容を掲載しています。なお、本資料は、AbbvieInc.、AstrazenecaPlc、BiomarinPharmaceuticalIn、ChiesiFarmaceuticiS.P.A.、DigestiveCare,Inc.、LeadiantBiosciences,Inc.、NestleHealthScience、PfizerInc.、SanofiS.A.、TakedaPharmaceuticalsなどの企業情報を含んでいます。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の酵素補充療法市場規模：製品別
- アガルシダーゼベータの市場規模
- イミグルセラーゼの市場規模
- ベラグルセラーゼアルファの市場規模
- イドゥルスルファーゼの市場規模
- その他製品の市場規模
・世界の酵素補充療法市場規模：疾患別
- ゴーシェ病における市場規模
- ファブリー病における市場規模
- ポンペ病における市場規模
- ムコ多糖症における市場規模
- その他疾患における市場規模
・世界の酵素補充療法市場規模：エンドユーザー別
- 病院における市場規模
- 輸液センター＆在宅医療における市場規模
・世界の酵素補充療法市場規模：地域別
- 北米の酵素補充療法市場規模
- ヨーロッパの酵素補充療法市場規模
- アジア太平洋の酵素補充療法市場規模
- 南米の酵素補充療法市場規模
- その他地域の酵素補充療法市場規模
・競争状況
・調査プロセス |
Global Enzyme Replacement Therapy Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. The “enzyme replacement therapy” refers to a medical procedure that uses human, animal, or recombinantly engineered enzymes to treat congenital enzyme deficiencies. The ERT core principle is the replacement of artificial enzyme in those with an enzyme deficiency. For ERT, the oral and intravenous methods of administration are widely utilized. The key factor driving the market growth is rising prevalence of rare diseases, availability of a wide range of enzyme replacement therapy and rising government initiatives for rare diseases. Thus, create the lucrative demand for the market during forecast period.
The presence of a large patient population suffering from rare lysosomal storage diseases creates high demand for effective treatments such as enzyme replacement therapy. The prevalence of several lysosomal storage disorders such Gaucher, Fabry, Pompe, and MPS is gradually rising on a global level. For instance, according to data released by Cleveland Clinic, in 2020, 6,000 persons in the United States have Gaucher disease, with 95% of them having type 1 Gaucher. A gradual increase in the diagnosis rate of rare diseases is also a result of growing government efforts and non-profit organizations in various nations to raise public awareness. As a result, these key aspects, as well as advantageous reimbursement policies and government support for medical care in developed nations, are increasing the rate of this therapy’s adoption and, as a result, propelling the market’s expansion over the projection period. Also, rising public awareness about enzyme replacement therapies would create the lucrative opportunities for the market during forecast period. However, the high cost of Enzyme Replacement Therapy stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Enzyme Replacement Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players and well-developed healthcare infrastructure in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as rising number of patients suffering from rare disorders and growing initiatives by other private organizations and the government for the awareness about this therapy would create lucrative growth prospects for the Enzyme Replacement Therapy market across Asia Pacific region.
Major market player included in this report are:
Abbvie Inc.
Astrazeneca Plc
Biomarin Pharmaceutical In
Chiesi Farmaceutici S.P.A.
Digestive Care, Inc.
Leadiant Biosciences, Inc.
Nestle Health Science
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceuticals
Recent Developments in the Market:
In 2021, Takeda Pharmaceutical Co. Ltd. announced a partnership deal with JCR Pharmaceuticals Co., Ltd., intending to commercialise JR-141 outside the U.S. to treatment of hunter syndrome.
In 2021, Clinigen Group plc. announced the manufacturing and distribution approval for hunterase ICV throughout Japan to treat patients with Hunter syndrome.
Global Enzyme Replacement Therapy Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Disease, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Agalsidase Beta
Imiglucerase
Velaglucerase Alfa
Idursulfase
Galsulfase
Laronidase
Others
By Disease:
Gaucher Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis
Exocrine Pancreatic Insufficiency (EPI)
Others
By End User:
Hospitals
Infusion Centers & Home Healthcare Setting
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Enzyme Replacement Therapy Market, by Region, 2019-2029 (USD Billion)
1.2.2. Enzyme Replacement Therapy Market, by Product, 2019-2029 (USD Billion)
1.2.3. Enzyme Replacement Therapy Market, by Disease, 2019-2029 (USD Billion)
1.2.4. Enzyme Replacement Therapy Market, by End User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Enzyme Replacement Therapy Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Enzyme Replacement Therapy Market Dynamics
3.1. Enzyme Replacement Therapy Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of rare diseases
3.1.1.2. Availability of a wide range of enzyme replacement therapy
3.1.2. Market Challenges
3.1.2.1. High cost of treatment
3.1.3. Market Opportunities
3.1.3.1. Rising public awareness about enzyme replacement therapies
Chapter 4. Global Enzyme Replacement Therapy Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Enzyme Replacement Therapy Market, by Product
6.1. Market Snapshot
6.2. Global Enzyme Replacement Therapy Market by Product, Performance – Potential Analysis
6.3. Global Enzyme Replacement Therapy Market Estimates & Forecasts by Product 2019-2029 (USD Billion)
6.4. Enzyme Replacement Therapy Market, Sub Segment Analysis
6.4.1. Agalsidase Beta
6.4.2. Imiglucerase
6.4.3. Velaglucerase Alfa
6.4.4. Idursulfase
6.4.5. Galsulfase
6.4.6. Laronidase
6.4.7. Others
Chapter 7. Global Enzyme Replacement Therapy Market, by Disease
7.1. Market Snapshot
7.2. Global Enzyme Replacement Therapy Market by Disease, Performance – Potential Analysis
7.3. Global Enzyme Replacement Therapy Market Estimates & Forecasts by Disease 2019-2029 (USD Billion)
7.4. Enzyme Replacement Therapy Market, Sub Segment Analysis
7.4.1. Gaucher Disease
7.4.2. Fabry Disease
7.4.3. Pompe Disease
7.4.4. Mucopolysaccharidosis
7.4.5. Exocrine Pancreatic Insufficiency (EPI)
7.4.6. Others
Chapter 8. Global Enzyme Replacement Therapy Market, by End User
8.1. Market Snapshot
8.2. Global Enzyme Replacement Therapy Market by End User, Performance – Potential Analysis
8.3. Global Enzyme Replacement Therapy Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
8.4. Enzyme Replacement Therapy Market, Sub Segment Analysis
8.4.1. Hospitals
8.4.2. Infusion Centers & Home Healthcare Setting
Chapter 9. Global Enzyme Replacement Therapy Market, Regional Analysis
9.1. Enzyme Replacement Therapy Market, Regional Market Snapshot
9.2. North America Enzyme Replacement Therapy Market
9.2.1. U.S. Enzyme Replacement Therapy Market
9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
9.2.1.2. Disease breakdown estimates & forecasts, 2019-2029
9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Enzyme Replacement Therapy Market
9.3. Europe Enzyme Replacement Therapy Market Snapshot
9.3.1. U.K. Enzyme Replacement Therapy Market
9.3.2. Germany Enzyme Replacement Therapy Market
9.3.3. France Enzyme Replacement Therapy Market
9.3.4. Spain Enzyme Replacement Therapy Market
9.3.5. Italy Enzyme Replacement Therapy Market
9.3.6. Rest of Europe Enzyme Replacement Therapy Market
9.4. Asia-Pacific Enzyme Replacement Therapy Market Snapshot
9.4.1. China Enzyme Replacement Therapy Market
9.4.2. India Enzyme Replacement Therapy Market
9.4.3. Japan Enzyme Replacement Therapy Market
9.4.4. Australia Enzyme Replacement Therapy Market
9.4.5. South Korea Enzyme Replacement Therapy Market
9.4.6. Rest of Asia Pacific Enzyme Replacement Therapy Market
9.5. Latin America Enzyme Replacement Therapy Market Snapshot
9.5.1. Brazil Enzyme Replacement Therapy Market
9.5.2. Mexico Enzyme Replacement Therapy Market
9.5.3. Rest of Latin America Enzyme Replacement Therapy Market
9.6. Rest of The World Enzyme Replacement Therapy Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Abbvie Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Astrazeneca Plc
10.2.3. Biomarin Pharmaceutical In
10.2.4. Chiesi Farmaceutici S.P.A.
10.2.5. Digestive Care, Inc.
10.2.6. Leadiant Biosciences, Inc.
10.2.7. Nestle Health Science
10.2.8. Pfizer Inc.
10.2.9. Sanofi S.A.
10.2.10. Takeda Pharmaceuticals
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
❖ 免責事項 ❖http://www.globalresearch.jp/disclaimer
